MedicoInsights’ Post

https://lnkd.in/gKbHyBTM Key insights: • Shuttle Pharma’s primary radiation sensitizer candidate for enhancing the effectiveness of radiation therapy (RT) in glioblastoma treatment is Ropidoxuridine, a potent option for addressing this incurable brain malignancy Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #drugapproval #HealthTrends #Insights #HealthIndustry #HealthInnovation #ShulterPharma #HealthcareAnalytics #NewsUpdate #clinicaltrials #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

Thoughts on this? >> Pointers to consider in SCLC developments >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #pharmaceutical #biotech #healthcare #pharma

Thoughts on this? >> Pointers to consider in SCLC developments >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #competitivemarketing #healthcare

The landscape of NSCLC treatment is evolving rapidly, and personalized medicine is at the forefront. Our latest blog post dives into a massive dataset of 80,000+ ALK, 35,000+ ROS1, 11,000+ EGFR, and more FISH results, shedding light on the prevalence of key mutations and the potential for more precise treatment plans. For pharmaceutical companies seeking to target clinicians and patients effectively, this data is a game-changer. Learn how these insights can revolutionize NSCLC care: https://bit.ly/3SkGEGT #NSCLC #PersonalizedMedicine #RealWorldData #PrognosHealth

Thoughts on this? >> Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #biotech #pharmaceutical #healthcare #competitivemarketing

Thoughts on this? >> Manali Kamdar, MD, on Bringing Liso-Cel to Earlier Lines of Treatment - CGTLive™ >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #competitivemarketing #pharma #pharmaceutical #healthcare

Phesi mid-year analysis reveals shift in clinical trial focus LINK: https://lnkd.in/eFMVqc9u Hashtags: #TodaysMedicalUpdate #Pharmaceutical #Medical #Research Please LIKE & REPOST

Phesi mid-year analysis reveals shift in clinical trial focus LINK: https://lnkd.in/emRyg4Kr Hashtags: #TodaysMedicalUpdate #Pharmaceutical #Medical #Research Please LIKE & REPOST

#JPM24: FDA's Peter Marks says some secondary cancer cases after CAR-T therapy may be 'causal,' but benefits still outweigh risks >>> lqventures.com #strategy #competitiveintelligence #marketing #biotech #pharmaceutical #healthcare #pharma #productmarketing

As early investors in Dyne Therapeutics, we are pleased to share they reported positive updates in their next-generation exon skipping program for Duchenne amenable to skipping exon 51. In their phase 1/2 Trial, Dyne-251 at dose of 10 mg/kg given once a month showed an average 3.2% normal dystrophin expression (7.6% normal dystrophin when adjusted for muscle content) at 6 months. Trends in functional improvements like the NSAA and other tests were observed, but non reached statistical significance at this time. Dyne-251 has fully enrolled cohorts for 20 and 40 mg/kg dosing and is reporting favorable safety profiles, while dystrophin and functional read outs for these higher doses will be coming in the future.    Dyne also reported positive safety, biomarker, functional, and patient reported outcome data in Type 1 Myotonic Dystrophy program (DM1), and anticipates providing updates by the end of the year on their plans for pursuing expedited FDA approvals in both DM1 and Duchenne. #FDA #DMD #DUCHENNE #CUREDUCHENNE #CLINICALTRIALS